URGN UroGen Pharma Ltd
Company Analysis
Latest News
🔴 UroGen Pharma is trading 10% down after cutting 2026 JELMYTO revenue outlook
UroGen Pharma is trading 10.37% down at $25.76 as investors continue reacting to its November 4 earnings and reduced 2026 JELMYTO outlook. - 2026 JELMYTO...
🔴 UroGen Pharma is trading 5.4% down on November 5, 2026 after a 2026 JELMYTO revenue guidance cut
UroGen Pharma is trading 5.36% down at $26.42 after third-quarter results and lower 2026 JELMYTO guidance. - ZUSDURI rose 35% sequentially to $68 million;...
🔴 UroGen Pharma is trading 17.93% down after Q3 loss and reduced full-year guidance
UroGen Pharma is trading at $28.08, down 17.93% on November 4, 2026, after third-quarter results missed estimates and full-year guidance was reduced. - The...
UroGen's ZUSDURI Surge Can't Mask a Fading Legacy Drug — Can One Product Carry the Whole Company?
Shares of UroGen Pharma plunged 10.1% to $30.92 in early trading November 4 after the specialty pharma company reported third-quarter results that missed on...
🔴 UroGen Pharma is trading 10.1% down in pre-market after Q3 earnings miss and lower JELMYTO guidance
UroGen Pharma is trading 10.1% lower at $30.92 after its November 4 third-quarter results missed estimates for total revenue and earnings, while management...
UroGen Pharma Ltd Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
UroGen Pharma is expected to report Q3 2026 revenue of approximately $90.25 million and a consensus EPS of $0.11, with the stock currently trading near $33.59...
🟢 UroGen Pharma is trading 5% up today amid Phase 1 dosing announcement
UroGen Pharma is trading at $34.41, up 5.17%, amid a positive market backdrop and its Phase 1 dosing update; no source explicitly links either to the move. -...
UroGen Reports 47.8-Month Median JELMYTO Response in Five-Year Study
UroGen Pharma announced final five-year results from the OLYMPUS long-term follow-up study of JELMYTO for low-grade upper tract urothelial cancer (LG-UTUC)....
🔴 UroGen Pharma is trading 5% down in pre-market — no clear catalyst identified
UroGen Pharma is trading 5.19% down at $32.00, based on supplied pre-market price context, with no clear overnight catalyst identified. - On October 28, the...
🔴 UroGen Pharma is trading 5.6% down in pre-market as no clear cause is established
UroGen Pharma is trading 5.63% down at $32.00 in pre-market; no clear cause is established. - Price context shows a pre-market decline from the October 27...
🔴 UroGen Pharma is trading 5% down with no clear company-specific catalyst identified
UroGen Pharma is trading 5.09% lower at $34.74, with no clear company-specific catalyst identified. - On October 16, 2026, the available news search surfaced...
🔴 UroGen Pharma is trading 10.88% down amid healthcare-sector weakness and risk-off concerns
UroGen Pharma is trading at $36.27, down 10.88%, amid healthcare-sector weakness and broader risk-off concerns. - No new company-specific announcement...
🔴 UroGen Pharma is trading 5% down
UroGen Pharma is trading 4.86% down now at $38.72, with no clear company-specific announcement explaining the move. - A recent UroGen investor conference...
🔴 UroGen Pharma is trading 4.5% down today amid Nasdaq losses and rising Treasury yields
UroGen Pharma is trading at $40.82, down 4.54%, with the decline appearing aligned with broader risk-off trading rather than a confirmed company-specific...
🟢 UroGen Pharma is trading 4.34% up today amid Nasdaq Composite's 0.67% rise
UroGen Pharma is trading 4.34% up now at $43.55, amid supportive broader-market conditions. - No fresh company-specific announcement was identified for...
🔴 UroGen Pharma is trading 4.11% down today — no clear company-specific catalyst
UroGen Pharma is trading 4.11% down at $43.15, with no clear company-specific announcement explaining the September 10, 2026 decline. - Scheduled to present...
🟢 UroGen Pharma is trading 4.14% up today ahead of Wells Fargo healthcare conference
UroGen Pharma is trading $45.63 (+4.14%) after opening-session gains on September 9, 2026; no new company-specific announcement or explicit catalyst was...
🟢 UroGen Pharma is trading 5% up today amid healthcare-sector strength
UroGen Pharma is trading at $45.54, up 4.96%, with healthcare up 1.26%, the clearest available explanation for the move. - Announced September...
🔴 UroGen Pharma is trading 4.1% down today — catalyst unclear
UroGen Pharma is trading 4.1% down at $43.62, with no clear company-specific catalyst identified for August 28, 2026. - Latest disclosures were the August 20...
🔴 UroGen Pharma is trading 4.67% down today amid renewed risk-off pressure
UroGen Pharma is trading 4.67% down at $47.94 as broader risk-off pressure returned, Treasury yields rose and major indexes declined. - On August 20, 2026,...